2Grundmann H, Aires de Sousa M, Boyce J, et al. Emer- gence and resurgence of meticillin-resistant Staphylococ- cus aureus as a public-health threat [ J ]. Lancet, 2006, 368 ( 9538 ) : 874-885.
3Marriott D J, Playford E G, Chen S. Determinants of mortality in non-neutropenic ICU patients with candidae- mia[J]. Crit Care, 2009,13(4) :R115.
4Moran C, Grussemeyer C A, Spalding J R. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infec- tions[J]. Am J Infect Control, 2010,38(1) :78-80.
5Chow J K, Golan Y, Ruthazer R, et al. Factors associat- ed with candidemia caused by non-albicans Candida spe- cies versus Candida albicans in the intensive care unit [J]. Clin Infect Dis, 2008,46(8) :1206-1213.
6Lee I, Fishman N O, Zaoutis T E, et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infec- tions[ J]. Arch Intern Med, 2009,169(4) :379-383.
7Falagas M E, Karageorgopoulos D E. Pandrug resistance (PDR) , extensive drug resistance (XDR) , and multi- drug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology [ J]. Clin Infect Dis, 2008,46 ( 7 ) : 1121-1122.
8Pfaller M A, Diekema D J, Gibbs D L. Geographic vari- ation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an as- sessment from the ARTEMIS DISK Global Antifungal Sur- veillance Program[ J ]. Diagn M icrobiol Infect Dis, 2010, 67(2) :162-171.
9Field J M, Hazinski M F, Sayre M R. Part 1 : executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardio- vascular Care[J]. Circulation, 2010,122( 18 Suppl 3) : S640-S656.
10Neumar R W, Otto C W, Link M S. Part 8: adult ad- vanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care[ J ]. Circulation, 2010,122( 18 Suppl 3) :S729-S767.
